Merck reported positive topline results from the Phase 3 ATLAS-UC induction-only study for tulisokibart. This investigational treatment targets patients with moderately to severely active ulcerative colitis. The trial met its primary endpoint of clinical remission at 12 weeks. It also successfully reached all key secondary endpoints.
Safety results showed no new concerns and remained consistent with Phase 2 findings. Tulisokibart is the first anti-TL1A monoclonal antibody to demonstrate clinical remission in a Phase 3 trial for this condition. The drug targets a specific cytokine linked to both inflammation and fibrosis.
These biological factors drive disease progression in inflammatory bowel diseases. Merck is also testing tulisokibart for Crohn's disease and other immune-mediated inflammatory conditions. The treatment serves as a core component of Merck’s expanding immunology portfolio.